Real Endpoints Symposium

Thursday, November 1 – Friday, November 2 2012
8:00 am – 12:45 pm

Location: Hyatt Regency Penn's Landing, Philadelphia

Ernst & Young will co-host a first annual symposium that will bring together senior executives from leading life sciences companies, payers, providers, and policy makers to discuss new solutions and innovative strategies for the rapidly changing reimbursement environment in healthcare. The event, entitled Disruptors: revolutionizing product reimbursement strategy, will be co-hosted by Real Endpoints, and will take place November 1-2, 2012 at the Hyatt Regency Penn's Landing in Philadelphia.

Scheduled presenters at the symposium include:

  • Lewis Sandy, MD - SVP, Clinical Advancement, UnitedHealth
  • Michael Sherman, MD - CMO, Harvard Pilgrim
  • Carolyn Clancy, MD - Director, AHRQ
  • Robert Galvin, MD - CEO, Equity Healthcare
  • Rob Epstein, MD - former CMO, Medco and president, Medco Research
  • Zeke Emanuel, MD - Chair, Dept of Medical Ethics and Health Policy, UPenn
  • Jeff Berkowitz - SVP, Pharmaceuticeutical Development and Market Access, Walgreen Co.
  • William Shrank, MD - Director, Rapid Cycle Innovation, CMS
  • Ira Klein, MD - Chief of Staff to CMO, Aetna
  • Martin Mackay, PhD - President, R&D, Astrazeneca
  • Annalisa Jenkins, MD - EVP, Head of Global Development, Merck Serono
  • Jack Bailey - SVP, Policy, Payers & Vaccines, GlaxoSmithKline
  • Steve Wooding - VP, Head of Market Access, Janssen EMEA, J&J


During the two day event, sessions will focus on the seven crucial product development and commercial issues that companies must deal with through 2014 and beyond, including:


  1. Disintermediating pharma: the pivotal new research role of payers in proving the value of emerging technologies
  2. Reimbursement bundling: the dramatic implications for product development and commercialization with the decline of fee-for-service medicine
  3. Getting off track – why what we believed about personalized medicine is only half true
  4. The evolving rules of comparative effectiveness and who will ultimately approve them
  5. Real world evidence: when it works, when it doesn’t, and what payers & providers will require
  6. Adherence – why it’s been such a bust for payers and for pharma…and why everyone now needs to take a second look.
  7. Payer/pharma risk-sharing – why it hasn’t worked … but why (and when) it will

To register for Disruptors: revolutionizing product reimbursement strategy, please visit

Follow the conversation at and on Twitter with #RESymp

Share MassBio